Primary endpoint
AMI
Inflammatory biomarkers decreased in both groups from baseline up to 26 weeks showing significant mean reduction of 35.1 ± 3.2% (p < 0.001) for IL-6, 57.4 ± 0.7% (p < 0.001) for hsCRP, 26.1 ± 0.7% (0.001) for neutrophils, 20.5 ± 0.6% (p < 0.001) for leukocytes, 10.2 ± 0.5% (p < 0.001) for NLR, and − 2.53 ± 0.92% for PLR (p = 0.006), but no significant difference between the Empagliflozin group and placebo was noted after 26 weeks. The reduction in inflammatory biomarkers occurred already at 6 weeks after AMI 
Mean ± SEM change in inflammatory markers over time by treatment *p = p-value for treatment-visit interaction, IL-6 and hsCRP values were log-transformed hsCRP, high sensitive c-reactive protein; IL-6, interlukin-6; NLR, neutrophil-lymphocyte ratio, PLR platelet to lymphocyte ratioMedian (IQR) 26-week IL-6 and hsCRP were numerically lower in the Empagliflozin group, but without a significant difference between both groups (p = 0.65 and p = 0.52, respectively). Likewise, neutrophils, leukocytes, NLR, and PLR were not significantly different between the groups at week 26 